Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
ATMARINOMED6
Thu, 05.12.2024
Marinomed Biotech AG
Korneuburg, Austria, December 5, 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital again by EUR 83,750 to EUR 1,778,333 by issuing 83,750 new no-par value bearer shares against cash contributions (the “Second Capital Increase”). The new shares will be issued fr [ … ]
Wed, 27.11.2024
Marinomed Biotech AG
Korneuburg, Austria, 27. November 2024 - Marinomed Biotech AG (the “Company”) announces that it has signed a binding term sheet with the European Investment Bank (EIB) for the intended issuance of a convertible bond (registered bond in the name or order) with a nominal value of EUR 423,840, which is to be subscribed exclusively by the European Inve [ … ]
Wed, 27.11.2024
Marinomed Biotech AG
Korneuburg, Austria, 27. November 2024 - As Marinomed Biotech AG (the "Company" or "Marinomed") announced in its ad hoc announcement dated 18 September 2024 regarding the first cash capital increase of 154,053 new shares (the "First Cash Capital Increase"), the Company is negotiating with investors regarding a possible second cash capital increase [ … ]
Tue, 26.11.2024
Marinomed Biotech AG
Korneuburg, Austria, November 26, 2024 - Marinomed Biotech AG (the “Company”) announces the signing of an agreement for the sale of its Carragelose business to French Unither Pharmaceuticals (“Unither”), a leading contract development and manufacturing organization (CDMO) of medical devices and pharmaceutical products. The contract provides for upf [ … ]
Thu, 14.11.2024
Marinomed Biotech AG
Korneuburg, Austria, November 14, 2024 - Marinomed Biotech AG (VSE:MARI) announces that the creditors' assembly unanimously approved the restructuring plan presented at the final court hearing at the Korneuburg Regional Court on November 14, 2024. The established quota is 30%, payable in several tranches within two years. 5% is to be deposited as a [ … ]
Fri, 11.10.2024
Marinomed Biotech AG
Korneuburg, Austria, 11. October 2024 - Marinomed Biotech AG (the "Company") announces that, after a thorough review of existing offers, the Management Board today decided to enter contract negotiations for the sale of the Carragelose portfolio in the form of an asset deal. The Company selected the potential buyer based on a combination of favorabl [ … ]
Wed, 18.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and [ … ]
Wed, 18.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and [ … ]
Sun, 15.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th [ … ]
Sun, 15.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th [ … ]